Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.39%, and the technology-dominated Nasdaq saw a decrease of 0.05%.Shares of the vaccine maker witnessed a loss of 23.51% over the previous month, trailing the performance of the Medical sector with its loss of 6.9% and the S&P 500's loss of 3.94%.The investment community will be closely monitoring the perfor ...

Core Insights - Novavax's non-mRNA JN.1 COVID-19 vaccine shows lower frequency and severity of short-term side effects compared to Pfizer-BioNTech's mRNA vaccine, with full results to be published later this year [1][3][4] Group 1: Study Findings - The SHIELD-Utah study indicates that Novavax recipients reported an average of 1.7 symptoms, while Pfizer-BioNTech recipients reported 2.8 symptoms [3] - 43.8% of Pfizer-BioNTech recipients experienced at least one symptom of Grade 2 or higher, compared to 24.2% of Novavax recipients [3] - Local reactogenicity events were 12.5% fewer in Novavax recipients compared to Pfizer-BioNTech recipients [3] - Novavax recipients experienced lower hours of reduced activity, with means of 0.7 hours missed work and 0.8 hours less productivity, compared to 1.4 hours and 2.4 hours for Pfizer-BioNTech recipients, respectively [3] Group 2: Company Strategy and Technology - Novavax focuses on leveraging its scientific expertise in vaccines and its technology platform, which includes protein-based nanoparticles and the Matrix-M adjuvant [5] - The company aims to build new partnerships through out-licensing its technology and vaccine assets, with a growing early-stage pipeline [5] - The SHIELD-Utah study adds to the body of research supporting the tolerability of Novavax's COVID-19 vaccine [4]

Shares of Novavax (NVAX) were down 19.6% on April 10 after the United States Health and Human Services (“HHS”) Secretary Robert F. Kennedy Jr., a well-known vaccine skeptic, raised concerns regarding the efficacy of the company’s protein-based COVID-19 vaccine.In a recent interview with CBS News, the HHS Secretary raised concerns about NVAX’s COVID-19 vaccine. He stated that it employs a single-antigen approach and mentioned that it has never worked for such respiratory diseases. The HHS Secretary also said ...

President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.However, not every beaten-down stock is worth investing in -- many look more like value traps than anything else, no matter how low their share prices have fallen. Consider two examples: Tilray (TLRY -2.65%) and Novavax (NVAX 4.81%). Both companies are trading well below $10 due to ...

Group 1: Novavax Stock Performance - Novavax (NVAX) shares increased by 11.4% to close at $6.24, following a significant trading volume compared to normal sessions, despite a 28.8% loss over the past four weeks [1][2] - The stock price recovery is attributed to a rebound after an 8-session decline, with investors optimistic about a favorable FDA decision regarding the company's protein-based COVID-19 vaccine [2] Group 2: Financial Expectations - Novavax is projected to report a quarterly loss of $0.43 per share, reflecting a year-over-year increase of 59.1%, while revenues are expected to be $72.27 million, down 23% from the previous year [3] - The consensus EPS estimate for Novavax has been revised 7.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Group 3: Industry Context - Novavax operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Travere Therapeutics (TVTX), experienced a 9.5% decline to $14.99, with a -12.6% return over the past month [4] - Travere's consensus EPS estimate remains unchanged at -$0.54, representing a year-over-year change of 69.3% [5]

Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. Meanwhile, the Dow lost 0.37%, and the Nasdaq, a tech-heavy index, lost 0.53%.Prior to today's trading, shares of the vaccine maker had gained 0.96% over the past month. This has outpaced the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03% in that time.The upcoming earnings release of Novavax will be of great ...

Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.Sometimes, corporations lag the broader market for good reasons. Maybe they aren't delivering strong financial results, or their prospects look increasingly dim. Investors want to stay away from these stocks even when they look like they hit rock bottom since they are unlikely to recover and deliver solid returns.With that in mind, let's cons ...

Dr. Young made the decision to resign from the board effective March 10, 2025. He has served on Novavax's board since 2010 and as Chair since 2011. During his tenure, the Company acquired Isconova and the Matrix-M™ adjuvant, now a key component of its technology platform. Novavax also earned global approvals for and commercialized its first vaccine ever for COVID-19, ramping up quickly to meet the demands of the global pandemic. Dr. Young helped to guide the Company through the partnership with Sanofi in 20 ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.Are these stocks worth buying in 2025 after their strong performance last year? My view is that only one of them looks attractive, while the other isn't worth the trouble. Here's why.The biotech stock to ...